Anna has a degree in Chemistry and a Ph.D. in Protein NMR from the University of Barcelona, Spain. She undertook her post-doc in protein NMR at the MRC Laboratory of Molecular Biology in Cambridge, UK, and following that worked in the Analytical R&D department of Pfizer for seven years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation. She received a Pfizer Worldwide Achievement Award for the implementation of reaction monitoring by NMR in an open access environment.
She joined Bruker in 2011 and had different roles since including Material Characterisation Laboratory Manager, Product Portfolio Manager and for several years was in charge of driving the Biopharmaceutical business at Bruker BioSpin. Anna recently moved to SciY as Senior Director of Strategy and Business Development.
How will AI-ready data enable the automation of drug discovery, development, and manufacturing? Imagine a world where self-driving labs uncover new drugs faster than ever before. The pharmaceutical industry is witnessing a paradigm shift with the adoption of AI-driven processes, enabling the discovery of new drugs in silico through intelligent engines, digital twins, and automation. However, the success of these models hinges on the quality and readiness of the data used. We will discuss how agnostic software solutions facilitate the capture, ingestion, and standardization of data, making it AI-ready and overcoming major bottlenecks in the digital transformation to self-driving labs. These advancements will pave the way for faster, more personalized medicine delivery.
For conference production and speaking opportunites:
For sponsorship and exhibition opportunities: